Reviewing Theratechnologies (THERF) and GlycoMimetics (GLYC)
Theratechnologies (OTCMKTS:THERF) and GlycoMimetics (NASDAQ:GLYC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.
This table compares Theratechnologies and GlycoMimetics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current recommendations for Theratechnologies and GlycoMimetics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
GlycoMimetics has a consensus price target of $28.00, indicating a potential upside of 104.53%. Given GlycoMimetics’ stronger consensus rating and higher possible upside, analysts plainly believe GlycoMimetics is more favorable than Theratechnologies.
Institutional & Insider Ownership
0.1% of Theratechnologies shares are owned by institutional investors. 26.1% of GlycoMimetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Volatility & Risk
Theratechnologies has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, GlycoMimetics has a beta of 3.23, suggesting that its share price is 223% more volatile than the S&P 500.
Earnings and Valuation
This table compares Theratechnologies and GlycoMimetics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Theratechnologies||$32.93 million||15.67||-$14.17 million||N/A||N/A|
Theratechnologies has higher revenue and earnings than GlycoMimetics.
GlycoMimetics beats Theratechnologies on 8 of the 12 factors compared between the two stocks.
Theratechnologies Inc., a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. The company's lead product is EGRIFTA, which increases the incidence or progression of diabetic retinopathy in diabetic HIV-infected patients with lipodystrophy and excess abdominal fat in the United States and Canada. Theratechnologies Inc. was founded in 1993 and is headquartered in Montreal, Canada.
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. Its advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and has evaluated in a Phase 3 clinical trial, conducted by its strategic collaboration with Pfizer Inc. The company's drug candidate, GMI-1271, an E-selectin antagonist, is evaluated in a Phase 1/2 clinical trial as a potential treatment for acute myeloid leukemia and is in a Phase 1 clinical trial for the treatment of multiple myeloma. It is also developing a Phase 1 clinical trial drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. It has a cooperative research and development agreement with the National Cancer Institute. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.